Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001705128 | SCV000251977 | uncertain significance | not provided | 2024-07-24 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 26867657, 33884488, 31106028, 36246636) |
Labcorp Genetics |
RCV001705128 | SCV003263316 | benign | not provided | 2023-11-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004737306 | SCV005357426 | uncertain significance | OPA1-related disorder | 2024-09-25 | no assertion criteria provided | clinical testing | The OPA1 c.619G>A variant is predicted to result in the amino acid substitution p.Glu207Lys. This variant has been reported in two patients with optic atrophy (Table S2, Wang et al. 2019. PubMed ID: 31106028; Xu et al. 2021. PubMed ID: 33884488) and in a patient with amblyopia along with a potentially causative variant in the LRP5 gene (described as p.Glu189Lys, Chen et al. 2022. PubMed ID: 36246636). This variant is reported in 0.092% of alleles in individuals of East Asian descent in gnomAD. Although we suspect this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |